Recent Cannabis Product Liability Class Action: A Cautionary Tale For Cannabis Companies

MT
McCarthy Tétrault LLP

Contributor

McCarthy Tétrault LLP provides a broad range of legal services, advising on large and complex assignments for Canadian and international interests. The firm has substantial presence in Canada’s major commercial centres and in New York City, US and London, UK.
As cannabis legalization moves north of the border, companies in Canada will inevitably face legal issues similar to those faced by their peers in the United States...
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

As cannabis legalization moves north of the border, companies in Canada will inevitably face legal issues similar to those faced by their peers in the United States, where the decriminalization of cannabis in several jurisdictions has been accompanied by a new set of product liability class actions.

A class action against a medical cannabis producer with headquarters in Moncton, New Brunswick was recently certified in Downton v Organigram, 2019 NSSC 4 – the first of its kind in Canada. The action was commenced after Organigram, in conjunction with Health Canada, issued voluntary recalls of a number of its products after some of the products were found to contain traces of pesticides that are not authorized for use on cannabis plants under the Pest Control Products Act, S.C. 2002, c. 28. Organigram found out about the trace pesticides when one of its wholesale recipients advised that one of its cannabis lots had been tested by a third-party laboratory. The plaintiff claimed that she suffered adverse health consequences as a result of consuming the recalled cannabis and claimed various remedies including general and punitive damages.

While the outcome of the action (and whether or not certification was appropriate, if the decision is appealed) has yet to be determined, the cautionary tale is clear: licensed producers must be aware of, and adhere to, the applicable pesticide regulations and should consider vigilant testing of crops to ensure all safety standards are met and are consistent with brand marketing. Class actions of this nature are by no means limited to medical cannabis producers, and may very well affect the recreational industry as well.

Our recent post on the Downton decision in our Canadian Class Actions Monitor blog contains further discussion as well as our prediction as to how the case law relating to cannabis product liability will develop.

To view the original article click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More